Dorzolamide/timolol

Drug Profile

Dorzolamide/timolol

Alternative Names: Cosopt; Cosopt Mini; Cosopt PF; L-671152/timolol; MK-507/timolol

Latest Information Update: 18 Dec 2015

Price : $50

At a glance

  • Originator Merck & Co; Merck Sharp & Dohme
  • Developer Akorn; Merck & Co; Merck Sharp & Dohme; Purdue Pharma; Santen Pharmaceutical; Sidus
  • Class Antiglaucomas; Propanolamines; Sulfonamides; Thiadiazoles; Thiophenes
  • Mechanism of Action Beta-adrenergic receptor antagonists; Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 09 Dec 2015 COSOPT® licensed to Purdue Pharma in Canada
  • 10 Mar 2015 Japanese Ministry of Health, Labour and Welfare approves a preservative free formulation of dorzolamide/timolol for treatment of Glaucoma and Ocular hypertension in Japan
  • 15 Aug 2014 Santen Pharmaceutical files for approval of a preservative-free formulation of Dorzolamide/timolol in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top